Kidney Transplants
Show Only Open Trials
1.
RESTARRT: Immunosuppression with Anti-thymocyte Globuline, Rituximab, Tacrolimus, and Sirolimus, Followed by Withdrawal of Tacrolimus and Sirolimus, in Living-donor Renal Transplant Recipients
- Study Status: Open to Enrollment
- Sponsor: NIAID; Immune Tolerance Network (ITN)
- Disease Status and/or Stage: Renal Transplant Recipients
2.
Use of PCR to Evaluate Renal Allograft Status (Diagnostic and Serial Biopsies)
- Study Status: Open to Enrollment
- Sponsor: NIH; Qatar National Research Foundation (QNRF); Quest Diagnostics, Inc.
3.
Evaluation of Subclinical Renal Allograft Damage
- Study Status: Open to Enrollment
- Sponsor: NIAID/NIH; Qatar National Research Foundation (QNRF)
